Skip to main content

Vaccines for the 21st Century A Tool for Decisionmaking (2000) / Chapter Skim
Currently Skimming:

Appendix 20: Respiratory Syncytial Virus
Pages 279-284

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 279...
... Disease Scenarios For the purposes of the calculation in this report, the committee described disease states associated with RSV infection as either a mild upper respiratory or related condition (pharyngitis/otitis media) or as bronchiolitis/pneumonia.
Read the entire page →
From page 280...
... It was assumed that while 100% of children 4 years of age and under receive treatment for lower respiratory infections, only 50% of people 5 years of age or older who are not hospitalized for lower respiratory RSV infections seek medical treatment. VACCINE DEVELOPMENT The committee assumed that it will take 7 years until licensure of a RSV vaccine and that $360 million needs to be invested.
Read the entire page →
From page 281...
... VACCINE PROGRAM CONSIDERATIONS Target Population For the purposes of the calculations in this report, it is assumed that the target population for this vaccine is all adolescent girls (age 12 years) and all infants.
Read the entire page →
From page 282...
... Table 4-1 summarizes vaccine program assumptions for all vaccines considered in this report. RESULTS If a vaccine program for RSV were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present value of the QALYs gained would be 33,000.
Read the entire page →
From page 283...
... Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the health care costs saved would be $490 million. If a vaccine program for RSV were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the program cost would be $1.05 billion.
Read the entire page →
From page 284...
... Immune Globulin Intravenous Therapy for RSV Lower Respiratory Tract Infection in Infants and Young Children at High Risk for Severe RSV Infections. Pediatrics 1997; 99:454-461.
Read the entire page →

Key Terms

  • vaccine program
  • syncytial virus
  • lower respiratory
  • rsv infections
  • target population

  • committee assumptions
  • using committee
  • including time
  • care costs
  • monetary costs

  • otitis media
  • million rsv
  • adolescent girls
  • respiratory infections
  • respiratory disease

  • physician visit
  • qaly gained
  • respiratory tract
  • costs similar
  • immune globulin

  • upper respiratory
  • infectious diseases
  • costs saved
  • vaccine development
  • program cost

  • summarizes vaccine
  • vaccines considered
  • tract infections
  • extra physician
  • described disease


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.